Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 39 min ago
Peer-reviewedCC BY-NC-NDJournal of immunotherapy and precision oncology

Evidence for Dose Optimization of Immune Checkpoint Inhibitors.

  • Sewanti Limaye1
  • Vanita Noronha2
  • Kumar Prabhash2
  1. 1Division of Medical and Precision Oncology, Sir HN Reliance Foundation Hospital and Research Center, Mumbai, India.
  2. 2Department of Medical Oncology, Tata Memorial Center, Homi Bhabha National Institute (HBNI), Mumbai, Maharashtra, India.
Read full textPDFDOICite

Related

  1. Rechallenge After Immune Checkpoint Inhibitors Myocarditis: Evidence and a Practical Framework
    Joe-Elie Salem, Stephane Ederhy, Meiying Zhang +1
    JACC: CardioOncologyPeer-reviewedCC BY-NC-ND 4.0Full text1 citedOncologyPMC
  2. Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study
    Jinyong Kim, Sehhoon Park, Gyeong-Won Lee +16
    JTO clinical and research reportsPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  3. Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study
    Jinyong Kim, MD, PhD, Sehhoon Park, MD, PhD, Gyeong-Won Lee, MD, PhD +16
    JTO Clinical and Research ReportsPeer-reviewedCC BY-NC-NDFull textOncologyDOAJEurope PMCPMC
  4. Editorial: Predictive biomarkers to immune checkpoint inhibitors in lung cancer
    Alessandro Russo, Christian Rolfo, Mariacarmela Santarpia
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  5. Commentary: Hemophagocytic lymphohistiocytosis induced by immune checkpoint inhibitors: observations and proposed clinical management
    Gauthier Coussement, Maxime Ilzkovitz, Loïc Baudelet +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineCrossrefDOAJ

Cite

BibTeXRIS
BibTeX
@article{limaye2026evidence,
  title = {{Evidence for Dose Optimization of Immune Checkpoint Inhibitors.}},
  author = {Sewanti Limaye and Vanita Noronha and Kumar Prabhash},
  journal = {Journal of immunotherapy and precision oncology},
  year = {2026},
  month = oct,
  doi = {10.36401/jipo-26-x7},
  url = {https://europepmc.org/article/MED/42872086},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Evidence for Dose Optimization of Immune Checkpoint Inhibitors.
AU  - Sewanti Limaye
AU  - Vanita Noronha
AU  - Kumar Prabhash
PY  - 2026
DA  - 2026/10/13
JO  - Journal of immunotherapy and precision oncology
DO  - 10.36401/jipo-26-x7
UR  - https://europepmc.org/article/MED/42872086
SN  - 2666-2345
SN  - 2590-017X
ER  -